Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.

Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS.

Gynecol Oncol. 2019 Jun 19. pii: S0090-8258(19)31257-0. doi: 10.1016/j.ygyno.2019.05.013. [Epub ahead of print]

PMID:
31229298
2.

Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?

Mills KA, Lopez H, Sun L, Cripe JC, Litz T, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Gynecol Oncol Rep. 2019 May 23;29:20-24. doi: 10.1016/j.gore.2019.05.007. eCollection 2019 Aug.

3.

Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?

Liang B, Lange SS, Massad LS, Dick R, Mills KA, Hagemann AR, McCourt CK, Thaker PH, Fuh KC, Mutch DG, Powell MA, Kuroki LM.

Gynecol Oncol Rep. 2019 Apr 24;28:136-140. doi: 10.1016/j.gore.2019.04.007. eCollection 2019 May.

4.

p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts.

Mills KA, Quinn JM, Roach ST, Palisoul M, Nguyen M, Noia H, Guo L, Fazal J, Mutch DG, Wickline SA, Pan H, Fuh KC.

Sci Rep. 2019 Mar 18;9(1):4762. doi: 10.1038/s41598-019-41122-3.

5.

Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis.

Natarajan S, Foreman KM, Soriano MI, Rossen NS, Shehade H, Fregoso DR, Eggold JT, Krishnan V, Dorigo O, Krieg AJ, Heilshorn SC, Sinha S, Fuh KC, Rankin EB.

Cancer Res. 2019 May 1;79(9):2271-2284. doi: 10.1158/0008-5472.CAN-18-2616. Epub 2019 Mar 12.

PMID:
30862717
6.

Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?

Cripe JC, Buchanan TR Jr, Wan L, Hagemann AR, McCourt CK, Massad LS, Fuh KC, Mutch DG, Powell MA, Thaker PH, Kuroki LM.

Gynecol Oncol Rep. 2019 Jan 26;28:1-5. doi: 10.1016/j.gore.2019.01.005. eCollection 2019 May.

7.

Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer.

Cripe JC, Buchanan TR Jr, Kuroki LM, Wan L, Mills KA, Massad L, Hagemann AR, Fuh KC, Mutch DG, Powell MA, Matsuo K, Thaker PH.

Gynecol Oncol. 2019 Apr;153(1):123-126. doi: 10.1016/j.ygyno.2019.01.009. Epub 2019 Jan 14.

PMID:
30651188
8.

Obesity counseling in obstetrics and gynecology: provider perceptions and barriers.

Huepenbecker SP, Wan L, Leon A, Rosen D, Hoff J, Kuroki LM, Fuh KC, Powell MA, Mutch DG, Colditz GA, Hagemann AR.

Gynecol Oncol Rep. 2018 Dec 10;27:31-34. doi: 10.1016/j.gore.2018.12.001. eCollection 2019 Feb. French.

9.

Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.

Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, Zhao P, Beck-Noia H, Hagemann IS, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2019 Feb;18(2):389-398. doi: 10.1158/1535-7163.MCT-18-0537. Epub 2018 Nov 26.

PMID:
30478151
10.

SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.

Mills KA, Roach ST, Quinn JM, Guo L, Beck HM, Lomonosova E, Ilivicky AR, Starks CM, Lawrence JA, Hagemann AR, McCourt C, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Gynecol Oncol. 2018 Nov;151(2):337-344. doi: 10.1016/j.ygyno.2018.08.008. Epub 2018 Sep 3.

11.

Gynecologic Oncologists' Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology.

Cripe JC, Mills KA, Kuroki LK, Wan L, Hagemann AR, Fuh KC, Mutch DG, Powell MA, Thaker PH.

Gynecol Obstet Invest. 2019;84(1):50-55. doi: 10.1159/000491089. Epub 2018 Aug 10. Review.

PMID:
30099446
12.

TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.

Grither WR, Divine LM, Meller EH, Wilke DJ, Desai RA, Loza AJ, Zhao P, Lohrey A, Longmore GD, Fuh KC.

Oncogene. 2018 Mar;37(13):1714-1729. doi: 10.1038/s41388-017-0043-9. Epub 2018 Jan 19.

13.

Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Palisoul ML, Quinn JM, Schepers E, Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC.

Mol Cancer Ther. 2017 Dec;16(12):2881-2891. doi: 10.1158/1535-7163.MCT-17-0587. Epub 2017 Sep 13.

14.

Radiation Therapy for Recurrent Clear-Cell Cancer of the Ovary.

Westhoff GL, Fuh KC, Longacre TA, McNally JL, Hsu IC, Kapp DS, Teng N, Chen LM.

Int J Gynecol Cancer. 2016 Nov;26(9):1608-1614.

PMID:
27575628
15.

AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer.

Divine LM, Nguyen MR, Meller E, Desai RA, Arif B, Rankin EB, Bligard KH, Meyerson C, Hagemann IS, Massad M, Thaker PH, Hagemann AR, McCourt CK, Powell MA, Mutch DG, Fuh KC.

Oncotarget. 2016 Nov 22;7(47):77291-77305. doi: 10.18632/oncotarget.12637.

16.

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.

Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K, Previs R, Tillmanns T, Kapp DS, Chan JK.

Gynecol Oncol. 2015 Dec;139(3):413-8. doi: 10.1016/j.ygyno.2015.06.041. Epub 2015 Jul 2.

PMID:
26144600
17.

Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States.

Fuh KC, Shin JY, Kapp DS, Brooks RA, Ueda S, Urban RR, Chen LM, Chan JK.

Gynecol Oncol. 2015 Mar;136(3):491-7. doi: 10.1016/j.ygyno.2014.10.009. Epub 2014 Oct 16.

PMID:
25455734
18.

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.

Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, LaGory EL, Kariolis MS, Chan A, Lindgren D, Axelson H, Miao YR, Krieg AJ, Giaccia AJ.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13373-8. doi: 10.1073/pnas.1404848111. Epub 2014 Sep 3.

19.

Utilization of and charges for robotic versus laparoscopic versus open surgery for endometrial cancer.

Yu X, Lum D, Kiet TK, Fuh KC, Orr J Jr, Brooks RA, Ueda SM, Chen LM, Kapp DS, Chan JK.

J Surg Oncol. 2013 May;107(6):653-8. doi: 10.1002/jso.23275. Epub 2012 Nov 5.

PMID:
23129514
20.

Current management of vulvar cancer.

Fuh KC, Berek JS.

Hematol Oncol Clin North Am. 2012 Feb;26(1):45-62. doi: 10.1016/j.hoc.2011.10.006. Review.

PMID:
22244661
21.

AXL is an essential factor and therapeutic target for metastatic ovarian cancer.

Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA, Giaccia AJ.

Cancer Res. 2010 Oct 1;70(19):7570-9. doi: 10.1158/0008-5472.CAN-10-1267. Epub 2010 Sep 21.

22.

Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial.

Collingham JP, Fuh KC, Caughey AB, Pullen KM, Lyell DJ, El-Sayed YY.

Obstet Gynecol. 2010 Jul;116(1):121-6. doi: 10.1097/AOG.0b013e3181e408f2.

PMID:
20567177
23.

Mesenteric hemodynamic response to circulatory shock.

Ceppa EP, Fuh KC, Bulkley GB.

Curr Opin Crit Care. 2003 Apr;9(2):127-32. Review.

PMID:
12657975
24.

Signal transduction by reactive oxygen species: alternative paradigms for signaling specificity.

Fuh KC, Meneshian A, Patel CB, Takiar V, Bulkley GB.

Surgery. 2002 Jun;131(6):601-12. Review. No abstract available.

PMID:
12075172
25.

The mesenteric hemodynamic response to circulatory shock: an overview.

Reilly PM, Wilkins KB, Fuh KC, Haglund U, Bulkley GB.

Shock. 2001 May;15(5):329-43. Review.

PMID:
11336191
26.

Hemodynamic pathogenesis of ischemic hepatic injury following cardiogenic shock/resuscitation.

Bailey RW, Brengman ML, Fuh KC, Hamilton SR, Herlong HF, Bulkley GB.

Shock. 2000 Oct;14(4):451-9.

PMID:
11049109
27.

Mesenteric vasoconstriction in response to hemorrhagic shock.

Toung T, Reilly PM, Fuh KC, Ferris R, Bulkley GB.

Shock. 2000;13(4):267-73.

PMID:
10774614
28.

Endothelial cells potentiate phagocytic killing by macrophages via platelet-activating factor release.

Owaki T, Meneshian A, Maemura K, Takao S, Wang D, Fuh KC, Bulkley GB, Klein AS.

Am J Physiol Heart Circ Physiol. 2000 Jan;278(1):H269-76.

Supplemental Content

Support Center